Skip to content
S4757Senate2023-2024 Session

Stop Addiction Drug Diversion

Official title

“Directs the commissioner of health to promulgate rules and regulations to reduce the diversion of addiction medications”

Sponsor Andrew J. LanzaSD-24+1 co-sponsorAffects Finance
Status
In Senate Committee
Finance
Impact
8/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Finance

What's happening

This bill requires the health commissioner to set new regulations for opioid addiction treatment to promote recovery and prevent diversion of addiction medicines.

Why it matters

  1. Empowers patients with informed choices. By mandating that all patients receive clear, documented information about every FDA-approved addiction medication, the bill aims to ensure individuals can make knowledgeable decisions about their treatment—potentially improving engagement and outcomes.

  2. Expands access and continuity of care. Requires providers to refer patients to other settings if they choose a medication not offered on-site, and mandates the use of standardized assessment tools and ongoing treatment plan reviews, promoting more consistent, individualized, and effective care across providers.

  3. Strengthens patient safety and accountability. Introduces diversion control practices (like prescription limits and toxicology screening) for take-home medications, aiming to minimize misuse and illegal distribution of addiction medicines while safeguarding patient health.

  4. Increases oversight and quality assurance. Establishes monitoring and penalties for provider compliance, signaling a significant increase in regulatory oversight that could raise standards across opioid addiction treatment but may also add administrative burdens for providers.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Watching

    Opioid treatment physicians and practices

    Covered providers would face counseling, treatment planning, diversion control and documentation requirements, with compliance monitoring and penalties for violations.

  • Patients seeking treatment for opioid use disorder

    They would receive explanations of FDA-approved medication options, referrals for preferred medications unavailable from their provider and information about peer recovery support services.

  • Watching

    Department of Health and Office of Addiction Services and Supports

    The health commissioner would develop rules in consultation with OASAS, arrange compliance monitoring and establish penalties, while OASAS would set treatment planning standards.

  • Qualified addiction professionals and OASAS-certified treatment programs

    They could provide required counseling through employment by medical practices or contracts with those practices.

Headline styles

Stop Addiction Drug Diversion

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Andrew J. Lanza

Senator · Senate District 24

1 Co-sponsor

History

  1. Reported and committed to finance
  2. Referred to alcoholism and substance use disorders
  3. Referred to alcoholism and substance use disorders

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

4757

2023-2024 Regular Sessions

IN SENATE

February 14, 2023

Introduced by Sen. LANZA -- read twice and ordered printed, and when printed to be committed to the Committee on Alcoholism and Substance Abuse

AN ACT to amend the public health law, in relation to directing the commissioner of the department of health to promulgate rules and regulations promoting recovery from opioid misuse and reducing diversion of addiction medicines

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The public health law is amended by adding a new section 3309-c to read as follows:

§ 3309-c. Promoting recovery from opioid misuse and reducing diversion of addiction medicines. 1. The commissioner shall, in consultation with the office of addiction services and supports, promulgate rules and regulations pertaining to individual physicians and group practices including, but not limited to, physician's office-based opioid treatment, opioid treatment programs and any other treatment practices serving more than fifty patients at a time who have a primary or secondary diagnosis of opiate misuse or addiction. Such rules and regulations shall at a minimum include the following provisions:

(a) All patients seeking treatment for opiate use disorder shall be given an orientation including factual information and an easily understood explanation of each addiction medication option approved by the United States food and drug administration. Such education must be documented in the patient record along with documentation regarding the patient's choice of one of the medication options or none of them. Such documentation shall be signed by the patient, or the commissioner may specify some other form of documentation showing that the medical provider made a good faith effort to obtain such informed consent from the patient;

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD08760-01-3

(b) If a patient chooses an addiction medication not available through the medical practitioner, such practitioner must make a referral to a treatment setting where the patient can access his or her preferred medication option;

(c) The medical provider shall utilize the level of care for alcohol and drug treatment referral web application provided by the office of addiction services and supports or another patient assessment instrument approved by the office of addiction services and supports to help determine an appropriate level of patient care;

(d) In the event that the patient using opiates declines to engage in treatment the medical provider shall provide such patient with information about accessible harm reduction services;

(e) Treatment counseling shall be provided to all individuals for whom an addiction medication is prescribed or dispensed. Such treatment counseling may be provided by a qualified addiction professional, as determined by the office of addiction services and supports, employed by the medical practice or through a contract with an office of addiction services and supports certified treatment program;

(f) The medical provider shall develop a treatment plan for each patient and such plan shall be reviewed, at a minimum, every six months. The standards for developing individual treatment plans shall be determined by the office of addiction services and supports and shall be consistent with the standards used in other office of addiction services and supports licensed outpatient treatment programs;

(g) The medical provider shall inform patients about available peer recovery support services; and

(h) When an addiction medication is not taken under direct clinical supervision, the medical provider shall utilize diversion control practices to ensure such medication is taken as prescribed and not diverted. Such practices shall be determined by the commissioner and shall include:

(i) limits on the amount of medication prescribed and the number of refills given to a patient until such patient has established a pattern of reliability; and

(ii) minimum toxicology screening standards.

2. For all medical providers subject to these rules and regulations, the commissioner shall ensure that providers are monitored for compliance. Such monitoring shall be done directly by the department or by an independent organization specified by the commissioner.

3. The commissioner shall establish appropriate penalties for medical practitioners who fail to comply with such rules and regulations promulgated under subdivision one of this section.

§ 2. This act shall take effect January 1, 2024. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to directing the commissioner of the department of health to promulgate rules and regu- lations promoting recovery from opioid misuse and reducing diversion of addiction medicines

Purpose or general idea of bill

Directs the New York State Health Commissioner to promulgate rules and regulation to reduce the diversion of addiction medications.

Summary of provisions

Section 1. This section amends the Public Health law by adding a new section, § 3309-b to promote recovery from opioid misuse and reduce the diversion of addiction medicines.

Section 2. This section provides the effective date.

Justification

The opioid epidemic has created the need to expand the availability of treatment for persons with substance use disorders. The Comprehensive Addiction Recovery Act enacted by Congress in 2016 includes a provision that permits individual and group medical practices to increase the number of patients they can treat with Buprenorphine products to 275 to address opioid addiction. With this expansion of treatment, it is imper- ative to implement quality standards that assure evidence-based clinical practice and proper safeguards to reduce diversion and risk for relapse. This legislation aims to establish clinical standards for these medial practices that include evidence-based treatment protocols recommended by the New York State Office of Alcoholism and Substance Abuse Services.

Prior legislative history

2022: S.6183- Referred to alcoholism & Substance Abuse

2021: S.6183- Referred to alcoholism & Substance Abuse

2020: S.3317 - Referred to alcoholism & Substance Abuse

2019: S.3317 - Referred to alcoholism & Substance Abuse

2018: S.6815 - Referred to Health / A.8566A - Referred to Alcoholism & Drug Abuse

2017: S.6815 - Referred to Rules / A.8566- Referred to Alcoholism & Drug Abuse

Fiscal implications for state and local governments

None.

Effective date

This act shall take effect January 1, 2023; Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.